The development of the SELEX technology and its application in clinical treatment

Abstract

Abstract: Based on the three-dimensional structure of oligonucleotide ligands, systematic evolution of ligands by exponential enrichment (SELEX) technology can screen for efficient and specific oligonucleotide aptamer to combine with molecular targets. Due to its high affinity, strong specificity, low immunogenicity, short filtering cycle and wide range of application, the ligands have several advantages and potential for new drugs in clinical diagnosis and treatment. In this article the application of oligonucleotide aptamer in the clinical treatment are reviewed from several aspects such as the development of the SELEX technology, modification of ligands, the advantages of clinical treatment, functions of ligands as target protein blocking agents and targeted drug delivery carrier.

Key words: SELEX, oligonucleotide aptamer, ligands, treatment

CLC Number:

R373

LONG Yu-peng, REN Jun. The development of the SELEX technology and its application in clinical treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 228-232.

References

[1] Shamah SM, Healy JM, Cload ST. Complex target SELEX[J]. Acc Chem Res, 2008, 41(1): 130-138.
[2] Cerchia L, Hamm J, Libri D, et al. Nucleic acid aptamers in cancer medicine[J]. FEBS Lett, 2002, 528(1/2/3): 12-16.
[3] Vu MM, Jameson NE, Masuda SJ, et al. Convergent evolution of adenosine aptamers spanning bacterial, human, and random sequences revealed by structure-based bioinformatics and genomic SELEX[J]. Chem Biol, 2012, 19(10): 1247-1254.
[4] Chen CK, Kuo TL, Chan PC, et al. Subtractive SELEX against two heterogeneous target samples: numerical simulations and analysis[J]. Comput Biol Med, 2007, 37(6): 750- 759.
[5] Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic[J]. Annu Rev Pharmacol Toxicol, 2010, 50: 237-257.
[6] Kuwahara M, Sugimoto N. Molecular evolution of functional nucleic acids with chemical modifications[J]. Molecules, 2010, 15(8): 5423-5444.
[7] Maasch C, Buchner K, Eulberg D, et al. Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications[J]. Nucleic Acids Symp Ser (Oxf), 2008, 52 (1): 61-62.
[8] Crouzier L, Dubois C, Edwards SL, et al. Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers[J]. PLoS One, 2012, 7(4): e35990.
[9] Ferapontova EE, Olsen EM, Gothelf KV. An RNA aptamer-based electrochemical biosensor for detection of theophylline in serum[J]. J Am Chem Soc, 2008, 130(13): 4256- 4258.
[10] Lauridsen LH, Veedu RN. Nucleic acid aptamers against biotoxins: a new paradigm toward the treatment and diagnostic approach[J]. Nucleic Acid Ther, 2012, 22(6): 371-379.
[11] Drolet DW, Jenison RD, Smith DE, et al. A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX)[J]. Comb Chem High Throughput Screen, 1999, 2(5): 271-278.
[12] Gold L, Janjic N, Jarvis T, et al. Aptamers and the RNA world, past and present[J]. Cold Spring Harbor Perspect Biol, 2012, 4(3): 1-9.
[13] Sundaram P, Kurniawan H, Byrne ME, et al. Therapeutic RNA aptamers in clinical trials[J]. Eur J Pharm Sci, 2013, 48(1/2): 259-271.
[14] Yang X, Li N, Gorenstein DG. Strategies for the discovery of therapeutic aptamers[J]. Expert Opin Drug Discov, 2011, 6(1):75-87.
[15] Keefe AD, Pai S, Ellington A. Aptamers as therapeutics[J]. Nat Rev Drug Discov, 2010, 9(7) : 537-550.
[16] Friberg TR, Tolentino M, Group LS. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study[J]. Br J Ophthalmol, 2010, 94(12): 1611-1617.
[17] Dobrovolsky AB, Titaeva EV, Khaspekova SG, et al. Inhibition of thrombin activity with DNA-aptamers[J]. Bull Exp Biol Med, 2009, 148(1): 33-36.
[18] Woodruff RS, Xu Y, Layzer J, et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer[J]. J Thromb Haemost, 2013, 11(7): 1364-1373.
[19] Trahtenherts A, Gal-Tanamy M, Zemel R. Inhibition of hepatitis C virus RNA replicons by peptide aptamers[J]. Antiviral Res, 2008, 77(3): 195-205.
[20] Jang KJ, Lee NR, Yeo WS, et al. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome(SARS)coronavirus NTPase/Helicase[J]. Biochem Biophys Res Commun, 2008, 366(3): 738-744.
[21] Gao T, Ning L, Li C, et al. A colorimetric method for protein assay via exonuclease III-assisted signal attenuation strategy and specific DNA-protein interaction[J]. Anal Chim Acta, 2013, 788: 171-176.
[22] McNamara JO, Kolonias D, Pastor F, et al. Multivalent 4-1BB binding aptamers costimulate CD₈⁺ T cells and inhibit tumor growth in mice[J]. J Clin Invest, 2008, 118(1): 376-386.
[23] Shangguan D, Meng L, Cao ZC, et al. Identification of liver cancer-specific aptamers using whole live cells[J]. Anal Chem, 2008,80 (3):721-728.
[24] Scaggiante B, Dapas B, Farra R, et al. Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors[J]. Curr Drug Metab, 2013, 14(5): 565-582.
[25] Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chembiochem, 2009, 10(5) : 862-868.
[26] Chu TC, Twu KY, Ellington AD, et al. Aptamer mediated siRNA delivery[J]. Nucl Acids Res, 2006, 34(10): 73-78.